Skip to main content
51 search results for:

Hormonal agents 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 30-06-2023 | Prostate cancer | News | Article

    First-line talazoparib plus enzalutamide supported for mCRPC

    The commentators note that “for patients with BRCA mutations, the rPFS benefit of combining [a next-generation hormonal agent] and a PARP inhibitor is now clear based on three phase 3 studies, but an overall survival benefit will be needed to confirm that earlier combination is favoured over the current practice of sequential use of these two active agents.”

  2. 05-06-2023 | Breast cancer | Conference coverage | Article
    ASCO 2023

    Adjuvant ribociclib reduces recurrence risk in early breast cancer

    Supplementing endocrine therapy with ribociclib significantly decreases the relapse risk in people with hormone receptor-positive, HER2-negative, early breast cancer.

  3. 08-12-2022 | SABCS 2022 | Conference coverage | Article

    monarchE 4-year results show abemaciclib benefit is maintained beyond treatment completion

    The 4-year results from monarchE indicate that the invasive disease-free survival gain offered by adjuvant abemaciclib in people with high-risk, hormone receptor-positive, HER2-negative, early breast cancer is maintained even after the 2-year treatment period.

  4. 09-12-2022 | SABCS 2022 | Conference coverage | Article

    Next-generation oral SERD shows promise in ER-positive, advanced breast cancer

    Treatment with the novel oral selective estrogen receptor degrader camizestrant significantly improves progression-free survival versus fulvestrant in patients with pretreated, estrogen receptor-positive, HER2-negative advanced breast cancer, shows a phase 2 study.

  5. 08-12-2022 | SABCS 2022 | Conference coverage | Article

    First-line ribociclib plus ET RIGHT Choice for aggressive advanced breast cancer

    Ribociclib plus endocrine therapy is associated with a significant progression-free survival benefit relative to combination chemotherapy in treatment-naïve patients with hormone receptor-positive, HER2-negative, advanced breast cancer with aggressive features, suggest trial data.

  6. 01-08-2022 | Breast cancer | News | Article

    Copy number heterogeneity may help inform adjuvant ET decisions in breast cancer

    A retrospective analysis points to the utility of intra-tumor copy number heterogeneity to identify patients with node-negative, estrogen receptor-positive breast cancer who may be able to forgo adjuvant endocrine therapy.

  7. 25-07-2022 | Breast cancer | News | Article

    Postmenopausal hormone therapy may be feasible for early-stage breast cancer survivors

    Postmenopausal women who use vaginal estrogen therapy or menopausal hormone therapy after surgery for early-stage, estrogen receptor-positive breast cancer may not have an increased risk for recurrence or death, suggest Danish investigators.

  8. 05-06-2022 | ASCO 2022 | Conference coverage | Article

    Ribociclib plus endocrine therapy switch benefits CDK4/6 progressors

    Patients with metastatic breast cancer who progress during combination treatment with a CDK4/6 inhibitor and endocrine therapy may benefit from switching endocrine therapy and combining it with ribociclib, MAINTAIN study findings indicate.

  9. 31-05-2022 | Breast cancer | News | Article
    News in brief

    Everolimus ‘not recommended’ in adjuvant early breast cancer setting

    The addition of everolimus to standard adjuvant endocrine therapy does not improve the outcomes of women with hormone receptor-positive, HER2-negative early breast cancer at high risk for recurrence, show phase 3 trial results.

  10. 18-05-2022 | Breast cancer | News | Article

    ABC–DO shows poor breast cancer treatment compliance in sub-Saharan Africa

    A high proportion of women with nonmetastatic breast cancer in sub-Saharan Africa do not initiate or complete treatment, show data from the African Breast Cancer–Disparities in Outcomes prospective cohort.

  11. 16-05-2022 | Breast cancer | News | Article

    WSG-ADAPT data may help guide chemotherapy use for HR-positive, HER2-negative EBC

    “These studies have the potential to identify resistance mechanisms in those patients with high Ki67 [post-ET] and to guide the selection of agents targeted to the respective mechanisms alongside their adjuvant endocrine treatment.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group J Clin Oncol 2022; doi:10.1200/JCO.21.02759 J Clin Oncol 2022; doi: 10.1200/JCO.22.00214

  12. 29-04-2022 | Prostate cancer | News | Article

    Pharmacovigilance data show prostate cancer hormone therapy link to neurocognitive decline

    Both traditional hormone therapy and novel androgen receptor signaling inhibitors may be associated with neurocognitive impairment in men with prostate cancer, suggests WHO pharmacovigilance data.

  13. 08-04-2022 | Breast cancer | News | Article

    monarchE PRO data bolster adjuvant abemaciclib use in early breast cancer

    The patient-reported outcomes from the monarchE trial add support for the addition of abemaciclib to endocrine therapy in the treatment of high-risk, early breast cancer, say the researchers.

  14. 16-03-2022 | Breast cancer | News | Article

    Endocrine therapy de-escalation a possibility for ER-low positive breast cancer

    Women with estrogen receptor-low positive breast cancer may be considered for 2 to 3 years of endocrine therapy rather than the standard 5 years without a negative impact on disease-free survival, Chinese researchers report.

  15. 01-03-2022 | EMA | News | Article
    approvalsWatch

    EMA recommends extension of abemaciclib indication

    Read about this breast cancer decision here

  16. 09-12-2021 | SABCS 2021 | Conference coverage | Article

    Novel SERD boosts PFS of patients with ER-positive, metastatic breast cancer

    A phase 3 trial has demonstrated a significant progression-free survival benefit with the oral SERD elacestrant relative to standard of care in pretreated patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.

  17. 26-11-2021 | Breast cancer | News | Article
    News in brief

    Breast cancer-related vertebral fracture risk characterized

    Physicians should be aware of the likelihood of pathologic etiology in advanced breast cancer patients who have sustained fractures of the vertebrae, say US researchers.

  18. 15-10-2021 | FDA | News | Article
    approvalsWatch

    Adjuvant abemaciclib gets go-ahead from FDA for early breast cancer

    Click here for more details on this approval

  19. 04-10-2021 | Breast cancer | News | Article

    Toxicity Index, PRO data shed light on early endocrine therapy discontinuations

    Toxicity Index data plus patient-reported outcomes may provide greater insights into reasons for early discontinuation of endocrine therapy than maximum-grade adverse event data alone, US study findings indicate.

  20. 03-08-2021 | Breast cancer | News | Article

    Baseline PROs predict early endocrine therapy discontinuation in breast cancer

    Patients with breast cancer may be at increased risk for early discontinuation of adjuvant endocrine therapy if they have depression, or poor physical or social wellbeing before treatment initiation, suggests a post-hoc analysis of the TAILORx trial.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.